Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis
CONCLUSIONS: Pomalidomide combined treatment regimens have shown good clinical efficacy, especially in pomalidomide + dexamethasone combined with other drugs. In terms of safety, it's important to pay attention to the likelihood of hematological adverse events when used clinically.PMID:38421372 | DOI:10.1080/17474086.2024.2326219 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - February 29, 2024 Category: Hematology Authors: Ying Luo Chen Li Yuanchen Niu Shuanzhi Wu Jingyuan Tian Zhiqin Hu Jin He Zhixin Zhang Haiyan Liu Yongmei Li Tenghua Wang Yi Fang Source Type: research
Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management
Expert Rev Hematol. 2024 Jan-Mar;17(1-3):55-66. doi: 10.1080/17474086.2024.2318345. Epub 2024 Feb 19.ABSTRACTINTRODUCTION: Immune thrombocytopenia (ITP), a disease that commonly presents with an increased risk of bleeding, can also paradoxically produce an increased risk of thromboembolic events. The risk of thromboembolism can be associated with patient-related factors (e.g. co-morbidities, age and history of thrombosis), disease-related factors (e.g. a greater proportion of younger, more reactive platelets, and the presence of microparticles and pro-inflammatory cytokines) and treatment-related factors (e.g. splenectomy,...
Source: Expert Review of Hematology - February 19, 2024 Category: Hematology Authors: Drew Provan Jecko Thachil Mar ía Teresa Álvarez Román Source Type: research
Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management
Expert Rev Hematol. 2024 Feb 19:1-12. doi: 10.1080/17474086.2024.2318345. Online ahead of print.ABSTRACTINTRODUCTION: Immune thrombocytopenia (ITP), a disease that commonly presents with an increased risk of bleeding, can also paradoxically produce an increased risk of thromboembolic events. The risk of thromboembolism can be associated with patient-related factors (e.g. co-morbidities, age and history of thrombosis), disease-related factors (e.g. a greater proportion of younger, more reactive platelets, and the presence of microparticles and pro-inflammatory cytokines) and treatment-related factors (e.g. splenectomy, thro...
Source: Expert Review of Hematology - February 19, 2024 Category: Hematology Authors: Drew Provan Jecko Thachil Mar ía Teresa Álvarez Román Source Type: research
